Document is current
Any future updates will be listed below
-
Authors
Shay, Timothy F. http://orcid.org/0000-0001-6591-3271
Jang, Seongmin http://orcid.org/0000-0002-9822-6790
Brittain, Tyler J. http://orcid.org/0000-0001-6411-999X
Chen, Xinhong
Walker, Beth
Tebbutt, Claire
Fan, Yujie
Wolfe, Damien A.
Arokiaraj, Cynthia M. http://orcid.org/0000-0003-3201-9868
Sullivan, Erin E.
Ding, Xiaozhe
Wang, Ting-Yu
Lei, Yaping
Chuapoco, Miguel R.
Chou, Tsui-Fen http://orcid.org/0000-0003-2410-2186
Gradinaru, Viviana http://orcid.org/0000-0001-5868-348X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (UF1MH128336, UF1MH128336)
Beckman Institute CLOVER Center
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (DP1NS111369)
- License Information
-
More Information
Article History
Received: 6 June 2024
Accepted: 27 August 2024
First Online: 8 September 2024
Competing interests
: The California Institute of Technology has a patent pending for the delivery methods identified in this manuscript, with T.F.S, X.C., S.J., and V.G. listed as inventors (PCT Patent Application No: PCT/US2024/0139329) and a provisional patent for the sequences described in this manuscript, with S.J., T.J.B., T.F.S., and V.G listed as inventors. V.G. is a co-founder and board of directors member of Capsida Therapeutics, a fully integrated AAV engineering and gene therapy company. T.F.S and V.G. are co-founders and X.C. and X.D. are co-founders and employees of Receptive Biotherapeutics. B.W. and C.T. are employees of Charles River Laboratories. The remaining authors declare no competing interests.
